Selective targeting of α4β1 integrin attenuates murine graft versus host disease

Leukemia. 2020 Nov;34(11):3100-3104. doi: 10.1038/s41375-020-0786-0. Epub 2020 Mar 9.

Authors

Bader Alahmari¹, Matthew L Cooper¹, Kiran Vij¹, Julie Ritchey¹, Peter Ruminski¹, Feng Gao², Jaebok Choi³, John F DiPersio⁴

Affiliations

¹ Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
² Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, 63110, USA.
³ Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, 63110, USA. jchoi25@wustl.edu.
⁴ Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, 63110, USA. jdipersi@wustl.edu.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Biomarkers
Disease Models, Animal
Disease Susceptibility*
Graft vs Host Disease / drug therapy*
Graft vs Host Disease / etiology*
H-2 Antigens / genetics
H-2 Antigens / immunology
Hematopoietic Stem Cell Transplantation
Integrin alpha4beta1 / antagonists & inhibitors*
Integrin alpha4beta1 / genetics
Integrin alpha4beta1 / metabolism
Mice
Molecular Targeted Therapy*
T-Lymphocytes / immunology
T-Lymphocytes / metabolism
Transplantation, Homologous

Substances

Biomarkers
H-2 Antigens
Integrin alpha4beta1

Grants and funding